Markets

Stock Alert: AC Immune Hits New 52-week High

(RTTNews) - Shares of Switzerland-based AC Immune SA (ACIU) are surging more than 68 percent or $4.93 in Thursday's morning trade at $12.12, after earlier touching a new 52-week high of $13.00.

Thursday, AC Immune said it has initiated the second highest dosing group in its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease or AD.

The clinical-stage biopharmaceutical company said that the decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group.

ACI-35.030, which is being developed by AC Immune in collaboration with Janssen Pharmaceuticals, Inc., is the first AD vaccine candidate designed to generate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain.

AC Immune has traded in a range of $4.07 to $13.00 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ACIU

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More